Biologic targeting in the treatment of inflammatory bowel diseases

References

• van AsscheGEmerging drugs to treat Crohn’s diseaseExpert Opin Emerging Drugs2007124959
   PubMed Web of Science ®Google Scholar
• HanauerSBPresentDHThe state of the art in the management of inflammatory bowel diseaseRev Gastroenterol Disord20033819212776005
   PubMedGoogle Scholar
• HanauerSBSandbornWJPractice Parameters Committee of the American College of Gastroenterology. Management of Crohn’s disease in adultsAm J Gastroenterol20019663564311280528
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGReview article: mild to moderate Crohn’s disease- defining the basis for a new treatment algorithmAliment Pharmacol Ther20031826327712895211
   PubMed Web of Science ®Google Scholar
• Camma’CGiuntaMRosselliMMesalamine in the maintenance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variablesGastroenterology1997113146514739352848
   PubMed Web of Science ®Google Scholar
• LochsHMayerMFleigWEProphylaxis of postoperative relapse in Crohn’s disease: European Cooperative Crohn’s Disease Study VIGastroenterology20001826427310648454
   PubMed Web of Science ®Google Scholar
• SteinRBHanauerSBMedical therapy for inflammatory bowel diseaseGastroenterol Clin North Am19992829732110372270
   PubMed Web of Science ®Google Scholar
• FaubionWAJrLoftusEVJrHarmsenWSThe natural history of corticosteroid therapy for inflammatory bowel disease: a population-based studyGastroenterology200112325526011487534
   PubMed Web of Science ®Google Scholar
• ArdizzoneSMolteniPImbesiVAzathioprine in steroid-dependent ulcerative colitisJ Clin Gastroenterol1997263303339412914
   PubMed Web of Science ®Google Scholar
• ArdizzoneSSamolvicoFBollaniSAzathioprine is more effective than oral 5-ASA in the treatment of steroid-dependent ulcerative colitisGastroenterology2001120A127
   Web of Science ®Google Scholar
• PearsonDCMayGRFickGHAzathiorprine and 6-mercaptopurine in Crohn’s disease. A meta-analyisisAnn Intern Med19951231321427778826
   PubMed Web of Science ®Google Scholar
• PearsonDCMayGRFickGHAzathioprine for maintaining remission of Crohn’s diseaseCochrane Database Syst Rev20002CD00006710796482
   PubMedGoogle Scholar
• D’HaensGLemmensLGeboesKIntravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitisGastroenterology20011201323132911313301
   PubMed Web of Science ®Google Scholar
• PresentDHMeltzerSJKrumholzMP6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicityAnn Intern Med19891116416492802419
   PubMed Web of Science ®Google Scholar
• FriedmanSGeneral principles of medical therapy of inflammatory bowel diseaseGastroenterol Clin North Am20043319120815177534
   PubMed Web of Science ®Google Scholar
• FeaganBGRochonJFedorakRNMethotrexate for the treatment of Crohn’s disease. The North American Crohn’s Disease Study Group InvestigatorsN Engl J Med19953322922977816064
   PubMed Web of Science ®Google Scholar
• FeaganBGFedorakRNIrvineEJA comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Disease Study Group InvestigatorsN Engl J Med20003421627163210833208
   PubMed Web of Science ®Google Scholar
• ArdizzoneSBollaniSManzionnaGInflammatory bowel disease approaching the 3rd millennium: pathogenesis and therapeutic implications?Eur J Gastroenterol Hepatol199911273210495168
   PubMed Web of Science ®Google Scholar
• FiocchiCInflammatory bowel disease: etiology and pathogenesisGastroenterology19981151822059649475
   PubMed Web of Science ®Google Scholar
• LimW-CHanauerSBEmerging biologics therapies in inflammatory bowel diseaseRev Gastroenterol Disord20044668515184826
   PubMedGoogle Scholar
• LarouxFSPavlikKPWolfREDysregulation of intestinal mucosal immunity: implications in inflammatory bowel diseaseNews Physiol Sci20011627227711719604
   PubMedGoogle Scholar
• HugotJPChamaillardMZoualiHAssociation of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s diseaseNature200141159960311385576
   PubMed Web of Science ®Google Scholar
• OguraYBonenDKInoharaNA frameshift mutation in NOD2 associated with susceptibility to Crohn’s diseaseNature200141160360611385577
   PubMed Web of Science ®Google Scholar
• van HeelDAMcGovernDPBJewellDPCrohn’s disease: genetic susceptibility, bacteria, and innate immunityLancet20013571902190411425408
   PubMed Web of Science ®Google Scholar
• MahidaYRJohalSNF-κB may determine whether epithelial cell-microbial interactions in the intestine are hostile or friendlyClin Exp Immunol200112334734911307797
   PubMed Web of Science ®Google Scholar
• BeutlerBAutoimmunity and apoptosis: the Crohn’s connectionImmunity20011551411485733
   PubMed Web of Science ®Google Scholar
• WeersmaRKStrokkersPCvan BodegravenAAMolecular prediction of risk and severity in a large Dutch Crohn’s disease cohortGut2008Sept 29 Epub ahead of print
   Web of Science ®Google Scholar
• ShanahanFCrohn’s diseaseLancet2002359626911809204
   PubMed Web of Science ®Google Scholar
• ElliottDEUrbanJrArgoCKDoes the failure to acquire helmintic parasites predispose to Crohn’s disease?FASEB J20004430435
   Google Scholar
• FranceschiSPanzaELa VecchiaCNon-specific inflammatory bowel disease and smokingAm J Epidemiol19871254454523812450
   PubMed Web of Science ®Google Scholar
• LindbergETyskCAndersonKSmoking and inflammatory bowel disease: a case control studyGut19882935273356367
   PubMed Web of Science ®Google Scholar
• MillerLGGoldsteinGMurphyMReversible alterations in immunoregulatory T cells in smoking: analysis by monoclonal antibodies and flow cytometryChest1982825265296982152
   PubMed Web of Science ®Google Scholar
• SrivastavaEDBartonJRO’MahonySSmoking, humoral immunity, and ulcerative colitisGut199132101610191916482
   PubMed Web of Science ®Google Scholar
• CopeGFHeatleyRVKelleherJKSmoking and colonic mucus in ulcerative colitisBMJ19862934813091168
   PubMed Web of Science ®Google Scholar
• CoulieBCamilleriMBharuchaAEColonic motility in chronic ulcerative proctosigmoiditis and the effects of nicotine on colonic motility in patients and healthy subjectsAliment Pharmacol Ther20011565366311328259
   PubMed Web of Science ®Google Scholar
• MadretsmaSWoltersLMvan DijkJPIn-vivo effect of nicotine on cytokine production by human non-adherent mononuclear cellsEur J Gastroenterol Hepatol19968101710208930570
   PubMed Web of Science ®Google Scholar
• PlevySThe immunology of inflammatory bowel diseaseGastroenterol Clin North Am200231779212122745
   PubMed Web of Science ®Google Scholar
• GokeMPodolskyDKRegulation of the mucosal epiothelial barrierBaillieres Clin Gastroenterol1996103934058905115
   PubMed Web of Science ®Google Scholar
• FabiaRArRajabAAnderssonM-LImpairment of bacterial flora in human ulcerative colitis and experimental colitis in the ratDigestion1993542482558243838
   PubMed Web of Science ®Google Scholar
• FussIJNeurathMBoirivantMDisparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5J Immunol1996157126112708757634
   PubMed Web of Science ®Google Scholar
• FarrellJRPeppercornMAUlcerative colitisLancet200235933134011830216
   PubMed Web of Science ®Google Scholar
• SartorRBPathogenesis and immune mechanisms of chronic inflammatory bowel diseasesAm J Gastroenterol19979212 SupplS511
   PubMed Web of Science ®Google Scholar
• DuchmannRMayEHeikeMT cell specifity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humansGut19994481281810323882
   PubMed Web of Science ®Google Scholar
• SchuppanDHahnEGMMPs in the gut: inflammation hits the matrixGut200047121410861255
   PubMed Web of Science ®Google Scholar
• PenderSLTickleSPDochertyAJA major role of matrix metallo-proteinases in T cell injury in the gutJ Immunol1997158158215909029093
   PubMed Web of Science ®Google Scholar
• PowrieFT cells in inflammatory bowel disease: protective and pathogenic rolesImmunity199531711747648390
   PubMed Web of Science ®Google Scholar
• BoirivantMMariniMDi FeliceGLamina propria T cell in Crohn’s disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosisGastroenterology199911655756510029614
   PubMed Web of Science ®Google Scholar
• InaKItohJFukushimaKResistance of Crohn’s disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalanceJ Immunol19991631081109010395708
   PubMed Web of Science ®Google Scholar
• BoirivantMPicaRDe MariaRStimulated human lamina propria T cells manifest enhanced Fas-mediated apoptosisJ Clin Invest199698261626228958226
   PubMed Web of Science ®Google Scholar
• UeyamaHKiyoharaTSawadaNFas ligand expression on lymphocytes in lesions of ulcerative colitisGut19984348539771405
   PubMed Web of Science ®Google Scholar
• KuhnRLohlerJRennickDInterleukin-10-deficient mice develop chronic enterocolitisCell1993752632748402911
   PubMed Web of Science ®Google Scholar
• GordonMSMcCaskill-StevensWJBattiatoLAA phase I trial of recombinant human interleukin-11 (neumega rhIl-11 growth factor) in women with breast cancer receiving chemotherapyBlood199687361536248611685
   PubMed Web of Science ®Google Scholar
• TrepicchioWLBozzaMPedneaultGRecombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide productionJ Immunol1996157362736348871663
   PubMed Web of Science ®Google Scholar
• PottenCSProtection of the small intestine clonogenic stem cells from radiation-induced damage by pretreatment with interleukin 11 also increases murine survival timeStem Cells1996144524598843547
   PubMed Web of Science ®Google Scholar
• QiuBSPfeifferCJKeithJCJrProtection by recombinant human interleukin-11 against experimental TNB-induced colitis in ratsDig Dis Sci199641162516308769290
   PubMed Web of Science ®Google Scholar
• KeithJCJrAlbertLMFerrantiTJRecombinant human interleukin-11 (rhIL-11) decreases inflammatory bowel disease in HLA-B27 transgenic rats (abstr)Gastroenterology1995108A846
   Web of Science ®Google Scholar
• ArdizzoneSBianchi PorroGInflammatory bowel disease: new insights into pathogenesis and therapyJ Intern Med200225247549612472908
   PubMed Web of Science ®Google Scholar
• NeurathMFFussIKelsallBLAntibodies to interleukin 12 abrogate established experimental colitis in miceJ Exp Med1995182128112907595199
   PubMed Web of Science ®Google Scholar
• MacDonaldTTMonteleoneGInterleukin-12 and Th1 immune responses in human Peyer’s patchesTrends Immunol20012224424711323280
   PubMed Web of Science ®Google Scholar
• PizarroTTMichieMHBentzMIL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn’s disease: expression and localization in intestinal mucosal cellsJ Immunol19991626829683510352304
   PubMed Web of Science ®Google Scholar
• SiegmundBFantuzziGRiederFNeutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-γ gamma and TNF-alpha productionAm J Physiol Regul Integr Comp Physiol2001281R1264R127311557635
   PubMed Web of Science ®Google Scholar
• SartorRBCytokines in intestinal inflammation: pathophysiological and clinical considerationsGastroenterology19941065335398299918
   PubMed Web of Science ®Google Scholar
• AmatiLCaradonnaLJirilloEImmunological disorders in inflammatory bowel disease and immunotherapeutic implicationsItal J Gastroenterol Hepatol19993131332510425578
   PubMed Web of Science ®Google Scholar
• PapadakisCATarganSATumor necrosis factor: biology and therapeutic inhibitorsGastroenterology20001191148115711040201
   PubMed Web of Science ®Google Scholar
• BlamMESteinRBSLichtensteinGRIntegrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectivesAm J Gastroenterol2001961977199711467623
   PubMed Web of Science ®Google Scholar
• LukacsNWChensueSWStrieterRMInflammatory granuloma formation is mediated by TNF-alpha-inducible intercellular adhesion molecule-1J Immunol1994152588358897911491
   PubMed Web of Science ®Google Scholar
• AlexopulouLPasparikisMKolliasGA murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signalingEur J Immunol199727258825929368614
   PubMed Web of Science ®Google Scholar
• van DeventerSJHA place for TACEGut2002515612077079
   PubMed Web of Science ®Google Scholar
• MossMLJinSLMillaMECloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alphaNature19973857337359034191
   PubMed Web of Science ®Google Scholar
• BlackRARauchCTKozloskyCJA metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cellsNature19973857297339034190
   PubMed Web of Science ®Google Scholar
• BrynskovJFoeghPPedersenGTumour necrosis factor α converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel diseaseGut200251374312077089
   PubMed Web of Science ®Google Scholar
• YamamotoMYoshozakiKKishimotoTIL-6 is required for the development of Th1 cell-mediated murine colitisJ Immunol20001644878488210779797
   PubMed Web of Science ®Google Scholar
• AtreyaRMudterJFinottoSBlockade of interleukin 6 trans signalling suppressor T cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn’s disease and experimental colitis in vivoNat Med2000658358810802717
   PubMed Web of Science ®Google Scholar
• MangelsdorfDJThummelCBeatoMThe nuclear receptor superfamily: The second decadeCell1995838358398521507
   PubMed Web of Science ®Google Scholar
• FajasLAuboeufDRaspeEThe organization, promoter analysis, and expression of the human PPArgamma geneJ Biol Chem19972721977919789
   Web of Science ®Google Scholar
• ButcherECPickerLJLymphocyte homing and homeostasisScience199627260668600538
   PubMed Web of Science ®Google Scholar
• SandbornWJYednockTANovel approaches to treating inflammatory bowel disease: targeting alpha-4 integrinAm J Gastroenterol2003982372238214638336
   PubMed Web of Science ®Google Scholar
• SandsBEBiologic therapy for inflammatory bowel diseaseInflamm Bowel Dis1997395113
   PubMed Web of Science ®Google Scholar
• BreedveldFCTherapeutic monoclonal antibodiesLancet200035573574010703815
   PubMed Web of Science ®Google Scholar
• DelvesPJRoittIMThe immune system, Second of two partsN Engl J Med200034310811710891520
   PubMed Web of Science ®Google Scholar
• DumontFJIDEC-131. IDEC/EisaiCurr Opin Investig Drugs20023725734
   PubMedGoogle Scholar
• DaneseSScaldaferriFVetranoACritical role of CD40 CD40 ligand pathway in regulating mucosal inflammation- driven angiogenesis in inflammatory bowel diseaseGut2007561248125617317789
   PubMed Web of Science ®Google Scholar
• DeuschKMautheBReiterCCD4-antibody treatment of inflammatory bowel disease: one year follow-upGastroenterology1993104A691
   Web of Science ®Google Scholar
• StronkhorstARademaSYongSLCD4 antibody treatment in patients with active Crohn’s disease: a phase I dose finding studyGut1997403203279135519
   PubMed Web of Science ®Google Scholar
• EmmrichJSeyfarthMFleigWETreatment of inflammatory bowel disease with anti-CD4 monoclonal antibodyLancet19913385705711678821
   PubMed Web of Science ®Google Scholar
• EmmrichJSeyfarthMLiebeSAnti-CD6 antibody treatment in inflammatory bowel disease without a long CD4+-cell depletionGastroenterology1995108A815
   Web of Science ®Google Scholar
• Canva-DelcambreVJacquotSRobinetETreatment of severe Crohn’s disease with anti-CD4 monoclonal antibodyAliment Pharmacol Ther1996107217278899079
   PubMed Web of Science ®Google Scholar
• KozuchPLHanauerSBGeneral principles and pharmacology of biologics in inflammatory bowel diseaseGastroenterol Clin N Am200635757773
   PubMed Web of Science ®Google Scholar
• PlevySESalzbergBAReguieroMA humanized anti-CD3 monoclonal antibody, visilizumab, for treatment of severe steroid-refractory ulcerative colitis: preliminary results of a phase I studyGastroenterology2003124A7
   Web of Science ®Google Scholar
• PlevySESalzbergBAVan AsscheGA phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, for treatment of severe steroid-refractory ulcerative colitisGastroenterology20071331414142217920064
   PubMed Web of Science ®Google Scholar
• van DeventerSJElsonCOFedorakRNMultiple doses of intravenous interleukin 10 in steroid-refractory Crohn’s disease. Crohn’s disease Study GroupGastroenterology19971133833929247454
   PubMed Web of Science ®Google Scholar
• SchreiberSFedorakRNNielsenOHSafety and efficacy of recombinant human interleukin 10 in chronic active Crohn’s diseaseGastroenterology200011914621472
   Web of Science ®Google Scholar
• FedorakRNGanglAElsonCORecombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn’s diseaseGastroenterology20001191473148211113068
   PubMed Web of Science ®Google Scholar
• FedorakNRNielsenOHWilliamsNCHuman recombinant interleukin-10 is safe and well tolerated but dose not induce remission in steroid dependent Crohn’s diseaseGastroenterology2001120A127
   Web of Science ®Google Scholar
• SchreiberSFedorakNRWildGUlcerative Colitis IL-10 Cooperative Study GroupSafety and tolerance of rHuIL-10 treatment in patients with mild/moderate active ulcerative colitisGastroenterology1998114A1080A1081
   Web of Science ®Google Scholar
• SteidlerLHansWSchotteLTreatment of murine colitis by Lactococcus lactis secreting interleukin-10Science20002891352135510958782
   PubMed Web of Science ®Google Scholar
• SandsBEBankSSninskyCAPreliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn’s diseaseGastroenterology1999117586410381910
   PubMed Web of Science ®Google Scholar
• SandsBEWinstonBSalzbergBRandomized, controlled trial of recombinant human interleukin 11 in patients with active Crohn’s diseaseAliment Pharmacol Ther20021639940611876692
   PubMed Web of Science ®Google Scholar
• HerrlingerKWitthoeftTRaedlerARandomized, double-blind, double-blind, controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn’s diseaseAm J Gastroenterol200610179379716635225
   PubMed Web of Science ®Google Scholar
• Van DullemenHMvan DeventerSJHHommesDWTreatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)Gastroenterology19951091291357797011
   PubMed Web of Science ®Google Scholar
• McCabeRPWoodyJvan DeventerSJHA multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn’s diseaseGastroenterology1996110A962
   Web of Science ®Google Scholar
• TarganSRHanauerSBvan DeventerSJHA short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s diseaseN Engl J Med1997337102910359321530
   PubMed Web of Science ®Google Scholar
• RutgeertsPD’HaensGTarganSEfficacy and safety or retreatment with anti-tumor necrosis factor antibody (Infliximab) to maintain remission in Crohn’s diseaseGastroenterology199911776176910500056
   PubMed Web of Science ®Google Scholar
• HanauerSBFeaganBGLichtensteinGRMaintenance Infliximab for Crohn’s disease: the ACCENT I randomised trialLancet20023591541154912047962
   PubMed Web of Science ®Google Scholar
• RutgeertsPFeaganBGLichtensteinGRComparison of scheduled and episodic treatment strategies of infliximab in Crohn’s diseaseGastroenterology200412640241314762776
   PubMed Web of Science ®Google Scholar
• SandsBEAndersonFHBernsteinCNInfliximab maintenance therapy for fistulizing Crohn’s diseaseN Engl J Med200435087688514985485
   PubMed Web of Science ®Google Scholar
• CheyWYHussainARyanCInfliximab for refractory ulcerative colitisAm J Gastroenterol2001962373238111513177
   PubMed Web of Science ®Google Scholar
• SandsBETremaineWJSandbornWJInfliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot studyInflamm Bowel Dis20017838811383595
   PubMed Web of Science ®Google Scholar
• RutgeertsPSandbornWJFeaganBGInfliximab for induction and maintenance therapy for ulcerative colitisN Engl J Med20053532462247616339095
   PubMed Web of Science ®Google Scholar
• GornetJMCouveSHassaniZInfliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre studyAliment Pharmacol Ther20031817518112869077
   PubMed Web of Science ®Google Scholar
• PapadakisKATreyzoneLAbreuMTInfliximab in the treatment of medically refractory indeterminate colitisAliment Pharmacol Ther20031874174714510748
   PubMed Web of Science ®Google Scholar
• RegueiroMValentineJPlevySInfliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel diseaseAm J Gastroenterol2003981821182612907338
   PubMed Web of Science ®Google Scholar
• LyonsJLRosenbraunJTUveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathyArch Ophthalmol199711561649006426
   PubMedGoogle Scholar
• Van den BoschFKruithofEDe VosMCrohn’s disease associated with spondyloarthropathy: effect of anti-TNF-alpha blockade with infliximab on articular symptomsLancet20003561821182211117919
   PubMed Web of Science ®Google Scholar
• HommesDWBaertFVan AsscheGTherapy management of recent onset Crohn’s disease: A controlled, randomized trial comparing step-up and top-down therapyGastroenterology2005129371
   Google Scholar
• SandbornWJFaubionWABiologics in inflammatory bowel disease: how much progress have we made?Gut2004531366137315306602
   PubMed Web of Science ®Google Scholar
• Sarzi PuttiniPArdizzoneSManzionnaGInfliximab-induced lupus in Crohn’s disease: a case reportDig Liver Dis20033581481714674674
   PubMedGoogle Scholar
• BaertFNomanMVermeireSInfluence of immunogenecity on the long-term efficacy of infliximab in Cronh’s diseaseN Engl J Med200334860160812584368
   PubMed Web of Science ®Google Scholar
• ParsiMAAchkarJPRichardsonSPredictors of response to infliximab in patients with Crohn’s diseaseGastroenterology200212370771312198696
   PubMed Web of Science ®Google Scholar
• VermeireSLouisECarbonezALogistic regression of clinical parameters influencing response to infliximabAm J Gastroenterol2002972357236312358256
   PubMed Web of Science ®Google Scholar
• TaylorKDPlevySEYangHANCA pattern and LTA aplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn’s diseaseGastroenterology20011201347135511313304
   PubMed Web of Science ®Google Scholar
• EstersNVermeireSJoossensSBelgian Group of Infliximab Expanded Access Program in Crohn’s DiseaseSerological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn’s diseaseAm J Gastroenterol2002971458146212094865
   PubMed Web of Science ®Google Scholar
• VermeireSLouisERutgeertsPThe NOD2 gene does not influence response to infliximab in Crohn’s diseaseGastroenterology200212310611112105838
   PubMed Web of Science ®Google Scholar
• MascherettiSHampeJCroucherPJResponse to infliximab treatment in Crohn’s disease is not associated with mutations in theCARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trialsPharmacogenetics20021250951212360101
   PubMedGoogle Scholar
• LouisEVermeireSRutgeertsPA positive response to infliximab in Crohn’s disease: association with higher systemic inflammation before treatment but not with −308 TNF gene polymorphismScand J Gastroenterol20023781882412190096
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGHanauerSBAn engineered human antibody to TNF (CDP571) for active Crohn’s disease: a randomised, palcebo-controlled trialGastroenterology20011201330133811313302
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGRadford-SmithGA randomized, placebo-controlled trial of CDP571, a humanized monoclonal antibody to TNF-α, in patients with moderate to severe Crohn’s diseaseGastroenterology2003124A61
   Web of Science ®Google Scholar
• FeaganBGSandbornWJBakerJA randomized, double-blind, placebo-controlled trial of CDP571, or steroid sparing and maintenance of remission in patients with steroid-dependent Crohn’s diseaseGastroenterology2000118A655
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGStoinovSPRECISE 1 Study InvestigatorsCertolizumab pegol for the treatment of Crohn’s diseaseN Engl J Med200735722823817634458
   PubMed Web of Science ®Google Scholar
• SchreiberSKhaliq-KareemiMLawranceICMaintenance therapy with certolizumab pegol for Crohn’s diseaseN Engl J Med200735723925017634459
   PubMed Web of Science ®Google Scholar
• IyerSKontoyannisDChevrierDInhibition of tumor necrosis factor mRNA translation by a rationally designed immunomodulatory peptideJ Biol Chem2000275170511705710748117
   PubMed Web of Science ®Google Scholar
• MurthySFlaniganACoppolaDRDP58, a locally active TNF inhibitor, is effective in the dextran sulphate mouse model of chronic colitisInflamm Res20025152253112540016
   PubMed Web of Science ®Google Scholar
• BourreilleADoubremelleMde la BletiereDRRDP58, a novel immunomodulatory peptide with anti-inflammatory effects. A pharmacological study in trinitrobenzene sulphonic acid colitis and Crohn’s diseaseScand J Gastroenetrol200338526532
   Web of Science ®Google Scholar
• TravisSPLYapLMHawkeyCJRDP-58: novel and effective therapy, for ulcerative coltis: results of parallel, prospective, placebo-controlled trialAm J Gastroenterol200398S239
   Google Scholar
• SandbornWJHanauerSBKatzSEtanercept for active Crohn’s disease: A randomised, double-blind, placebo-controlled trialGastroenterology20011211088109411677200
   PubMed Web of Science ®Google Scholar
• RutgeertsPLemmensIvan AsscheGTreatment of active Crohn’s disease with onercept (recombinant human soluble p55 tumor necrosis factor receptor): results of a randomized, open-label, pilot studyAliment Pharmacol Ther20031718519212534402
   PubMed Web of Science ®Google Scholar
• RutgeertsPSandbornWJFedorakRNOnercept for moderate-to-severe-Crohn’s disease: a randomized, double-bind, placebo-controlled trialClin Gastroenterol Hepatol2006488889316797249
   PubMed Web of Science ®Google Scholar
• SandbornWJHanauerSBLoftusEVAn open-label study of the human anti-TNF monoclonal antibody adalimumab subjects with prior loss of response or intolerance to infliximab for Crohn’s diseaseAm J Gastroenterol2004991984198915447761
   PubMed Web of Science ®Google Scholar
• HanauerSBSandbornWJRutgeertsPHuman anti-TNF monoclonal antibody (Adalimumab) in Crohn’s disease: the CLASSIC I trialGastroenterology200613032333316472588
   PubMed Web of Science ®Google Scholar
• SandbornWJHanauerSBRutgeertsPAdalimumab for maintenence treatment of Crohn’s disease: results of the CLASSIC II trialGut2007561232123917299059
   PubMed Web of Science ®Google Scholar
• ColombelJFSandbornWJRutgeertsPAdalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trialGastroenterology2007132526517241859
   PubMed Web of Science ®Google Scholar
• ItoHTakazoeMFukudaYEffective treatment of active Crohn’s disease with humanized monoclonal antibody MRA to interleukin-6 receptor: a randomized plcebo-controlled trialGastroenterology2003124A25
   Web of Science ®Google Scholar
• van AsscheGDalleINomanMA pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitisAm J Gastroenetrol200398369376
   Web of Science ®Google Scholar
• Van AsscheGSandbornWJFeaganBGDaclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo-controlled, dose ranging trialGut2006551568157416603634
   PubMed Web of Science ®Google Scholar
• CreedTJNormanMRProbertCSBasiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitisAliment Pharmacol Ther20031818651875
   Web of Science ®Google Scholar
• MannonPJFussIJMayerLAnti-interleukin-12 antibody for active Crohn’s diseaseN Engl J Med2004352069207915537905
   PubMed Web of Science ®Google Scholar
• RutgeertsPReinischWColombelJFPreliminary results of a phase I/II study of Huzaf, an anti-IFN-monoclonal antibody, in patients with moderate to severe active Crohn’s diseaseGastroenterology2002122A61
   Web of Science ®Google Scholar
• Van AsscheGPearceTFontolizumab (Huzaftm), a humanized anti-IFN-gamma antibody, has clinical activity and excellent tolerability in moderate to severe Crohn’s diseaseGut200453Suppl VIA48
   Google Scholar
• GhoshSGoldinEGordonFHNatalizumab for active Crohn’s diseaseN Engl J Med2003348243212510039
   PubMed Web of Science ®Google Scholar
• GordonFHLaiCWHamiltonMIA randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn’s diseaseGastroenterology200112126827411487536
   PubMed Web of Science ®Google Scholar
• RutgeertsPColombelJFEnnsRSubanalysis from a phase 3 study on the evaluation of natalizumab in active Crohn’s disease therapy-1 (ENACT-1)Gut200352Suppl VIA239
   Google Scholar
• Elan and Biogen Idec announce ANTEGREN-natalizumab-phase III maintenance trial in Crohn’s disease met its primary endpoint2004Accessed on Dec 3, 2008 Available from: htpp://www.elan.com
   Google Scholar
• RutgeertsPEnnsRColombelJF6-months steroid-sparing results of natalizumab in a controlled study of patients with Crohn’s diseaseGut200453Suppl VIA48
   Google Scholar
• GordonFHHamiltonMIDonoghueSA pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrinAliment Pharmacol Ther20021669970511929387
   PubMed Web of Science ®Google Scholar
• FeaganBGGreenbergGWildGEfficacy and safety of humanized alpha4 beta7 antibody in active Crohn’s diseaseGastroenterology2003124A25
   Web of Science ®Google Scholar
• FeaganBCMcDonaldJGreenbergGAn ascending dose trial of a humanized A4B7 antibody in ulcerative colitis (UC)Gastroenterology2001118A874
   Web of Science ®Google Scholar
• BennetCFCondonTPGrimmSInhibition of endothelial cell adhesion molecule expression with antisense oligonucleotidesJ Immunol1994152353035407511650
   PubMed Web of Science ®Google Scholar
• YacyshynBRBowen-YacyshynMBA placebo- controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn’s diseaseGastroenterology1998114113142
   Web of Science ®Google Scholar
• SchreiberSNikolausSMalchowHAbsence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn’s diseaseGastroenterology20011201339134611313303
   PubMed Web of Science ®Google Scholar
• YacyshynBRCheyWYGoffJDouble-blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn’s diseaseGut200251303612077088
   PubMed Web of Science ®Google Scholar
• Van DeventerSJTamiJAWedelMKA randomised, controlled, double-bind, escalating dose study of alicaforsen enema in ulcerative colitisGut2004531646165115479686
   PubMed Web of Science ®Google Scholar
• BeckPLPodolskyDKGrowth factors in inflammatory bowel diseaseInflamm Bowel Dis19995446010028449
   PubMed Web of Science ®Google Scholar
• SlonimAEBuloneLDamoreMBA preliminary study of growth hormone therapy for Crohn’s diseaseN Engl J Med20003421664166610833215
   PubMed Web of Science ®Google Scholar
• SinhaANightgaleJWestKPEpidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitisN Engl J Med200334935035712878742
   PubMed Web of Science ®Google Scholar
• KorzenicJRDieckgraefeBKIs Crohn’s disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn’s diseaseDig Dis Sci2000451121112910877227
   PubMed Web of Science ®Google Scholar
• DieckgraefeBKKorzenikJRHusainAAssociation of glycogen storage disease 1b and Crohn’s disease: results of a North American surveyEur J Pediatr2002161Suppl 1S88S9212373579
   PubMed Web of Science ®Google Scholar
• DieckgraefeBKKorzenikJRTreatment of active Crohn’s disease with recombinant human granulocyte-macrophage colony-stimulating factorLancet20023601478148012433518
   PubMed Web of Science ®Google Scholar
• KorzenicJRDieckgraefeBKImmunostimulation in Crohn’s disease: results of a pilot study of G-CSF (R-Methug-CSF) in mucosal and fistulizing Crohn’s diseaseGastroenterology2001118A874
   Web of Science ®Google Scholar
• KorzenikJDieckgraefeBValentineJSargramostim induces response and remission in patients with moderately-to-severely active Crohn’s disease (CD): results from a randomized, double-blind, placebo-controlled trialGut200453Suppl VIA49
   Google Scholar